Denali Therapeutics Inc
NASDAQ:DNLI
Intrinsic Value
Denali Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of a portfolio of product candidates for neurodegenerative diseases. [ Read More ]
The intrinsic value of one DNLI stock under the Base Case scenario is 24.53 USD. Compared to the current market price of 20.52 USD, Denali Therapeutics Inc is Undervalued by 16%.
Valuation Backtest
Denali Therapeutics Inc
Run backtest to discover the historical profit from buying and selling DNLI stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
Denali Therapeutics Inc
Current Assets | 1.1B |
Cash & Short-Term Investments | 1B |
Other Current Assets | 29.6m |
Non-Current Assets | 89.8m |
PP&E | 71.6m |
Other Non-Current Assets | 18.1m |
Current Liabilities | 78m |
Accounts Payable | 9.5m |
Accrued Liabilities | 68.5m |
Non-Current Liabilities | 45m |
Other Non-Current Liabilities | 45m |
Earnings Waterfall
Denali Therapeutics Inc
Revenue
|
330.5m
USD
|
Operating Expenses
|
-527.2m
USD
|
Operating Income
|
-196.7m
USD
|
Other Expenses
|
51.5m
USD
|
Net Income
|
-145.2m
USD
|
Free Cash Flow Analysis
Denali Therapeutics Inc
What is Free Cash Flow?
DNLI Profitability Score
Profitability Due Diligence
Denali Therapeutics Inc's profitability score is 17/100. The higher the profitability score, the more profitable the company is.
Score
Denali Therapeutics Inc's profitability score is 17/100. The higher the profitability score, the more profitable the company is.
DNLI Solvency Score
Solvency Due Diligence
Denali Therapeutics Inc's solvency score is 81/100. The higher the solvency score, the more solvent the company is.
Score
Denali Therapeutics Inc's solvency score is 81/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
DNLI Price Targets Summary
Denali Therapeutics Inc
According to Wall Street analysts, the average 1-year price target for DNLI is 44.75 USD with a low forecast of 26.26 USD and a high forecast of 99.75 USD.
Ownership
DNLI Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Shareholder Return
DNLI Price
Denali Therapeutics Inc
Average Annual Return | 57.02% |
Standard Deviation of Annual Returns | 183.61% |
Max Drawdown | -83% |
Market Capitalization | 2.8B USD |
Shares Outstanding | 139 160 000 |
Percentage of Shares Shorted | 7.55% |
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Denali Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of a portfolio of product candidates for neurodegenerative diseases. The company is headquartered in South San Francisco, California and currently employs 380 full-time employees. The company went IPO on 2017-12-08. The firm is focused on the discovery and development of therapies for patients with neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis (ALS) and others. The firm clinical programs include leucine-rich repeat kinase 2 (LRRK2) inhibitor program, eukaryotic initiation factor 2 B (EIF2B) activator program, enzyme transport vehicle: iduronate 2-sulfatase (ETV:IDS) program, receptor interacting serine/threonine protein kinase 1 (RIPK1) inhibitor program and second non-CNS penetrant RIPK1 inhibitor. The firm engineers its product candidates to cross the blood-brain barrier (BBB), and act directly in the brain. Its pipeline includes approximately 15 programs that are based on its TV technology, including the lead program ETV:IDS (DNL310). Its product pipeline includes DNL151, DNL593 (PTV:PGRN), DNL126 (ETV:SGSH), DNL919 (ATV:TREM2), DNL788, DNL343, DNL758 and others.
Contact
IPO
Employees
Officers
The intrinsic value of one DNLI stock under the Base Case scenario is 24.53 USD.
Compared to the current market price of 20.52 USD, Denali Therapeutics Inc is Undervalued by 16%.